Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM
| Autor: | Genovefa Kolovou, Samia Mora, Børge G. Nordestgaard, Alan T. Remaley, Christopher J. Duff, Emilio Ros, Florian Kronenberg, Gerald F. Watts, Christa M. Cobbaert, Eric Bruckert, Pia R. Kamstrup, Kristin M. Aakre, Jan Borén, Hannsjörg Baum, Sanja Stankovic, Alberico L. Catapano, Olov Wiklund, Nader Rifai, M. John Chapman, Angelika Hammerer-Lercher, Paul Collinson, Ana Stavljenić-Rukavina, Olivier S. Descamps, Kari Pulkki, Päivi Laitinen, Michel Langlois, Anne Langsted, Arnold von Eckardstein, Grazyna Sypniewska |
|---|---|
| Přispěvatelé: | UCL - (SLuc) Service de pathologie cardiovasculaire |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Apolipoprotein B Clinical Biochemistry Pre-Analytical Phase Familial hypercholesterolemia 030204 cardiovascular system & hematology LDL-CHOLESTEROL chemistry.chemical_compound 0302 clinical medicine lipoprotein(a) Medicine and Health Sciences apolipoprotein B 030212 general & internal medicine FAMILIAL HYPERCHOLESTEROLEMIA Societies Medical Hypolipidemic Agents biology Atherosclerotic cardiovascular disease atherosclerotic cardiovascular disease Lipoprotein(a) General Medicine 3. Good health remnant cholesterol LDL cholesterol Cardiology lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine medicine.medical_specialty CARDIOVASCULAR RISK REDUCTION Consensus Lipoproteins Hyperlipidemias CLINICAL-CHEMISTRY 03 medical and health sciences Internal medicine medicine Humans CORONARY-HEART-DISEASE NUCLEAR-MAGNETIC-RESONANCE non-HDL cholesterol Apolipoproteins B Cholesterol DIVISION WORKING GROUP Hypertriglyceridemia Biochemistry (medical) Cholesterol HDL Cholesterol LDL medicine.disease Atherosclerosis APOLIPOPROTEIN-B LEVELS Residual risk 030104 developmental biology chemistry biology.protein Hydroxymethylglutaryl-CoA Reductase Inhibitors TRIGLYCERIDE-RICH LIPOPROTEINS Biomarkers Lipoprotein |
| Zdroj: | Clinical chemistry and laboratory medicine, Vol. 58, no.4, p. 496-517 (2020) CLINICAL CHEMISTRY AND LABORATORY MEDICINE Clinical Chemistry and Laboratory Medicine, 58(4), 496-517. WALTER DE GRUYTER GMBH Atherosclerosis, Vol. 294, p. 46-61 (2020) Atherosclerosis, 294, 46-61. ELSEVIER IRELAND LTD Langlois, M R, Nordestgaard, B G, Langsted, A, Chapman, M J, Aakre, K M, Baum, H, Borén, J, Bruckert, E, Catapano, A, Cobbaert, C, Collinson, P, Descamps, O S, Duff, C J, von Eckardstein, A, Hammerer-Lercher, A, Kamstrup, P R, Kolovou, G, Kronenberg, F, Mora, S, Pulkki, K, Remaley, A T, Rifai, N, Ros, E, Stankovic, S, Stavljenic-Rukavina, A, Sypniewska, G, Watts, G F, Wiklund, O, Laitinen, P & European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative 2020, ' Quantifying atherogenic lipoproteins for lipid-lowering strategies : consensus-based recommendations from EAS and EFLM ', Clinical Chemistry and Laboratory Medicine, vol. 58, no. 4, pp. 496-517 . https://doi.org/10.1515/cclm-2019-1253 |
| ISSN: | 1434-6621 1437-4331 |
| DOI: | 10.1515/cclm-2019-1253 |
| Popis: | The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory diagnostics of atherogenic lipoproteins. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDLC), LDL cholesterol (LDLC), and calculated non-HDLC (=total – HDLC) constitute the primary lipid panel for estimating risk of atherosclerotic cardiovascular disease (ASCVD) and can be measured in the nonfasting state. LDLC is the primary target of lipid-lowering therapies. For on-treatment follow-up, LDLC shall be measured or calculated by the same method to attenuate errors in treatment decisions due to marked between-method variations. Lipoprotein(a) [Lp(a)]-cholesterol is part of measured or calculated LDLC and should be estimated at least once in all patients at risk of ASCVD, especially in those whose LDLC declines poorly upon statin treatment. Residual risk of ASCVD even under optimal LDL-lowering treatment should be also assessed by non-HDLC or apolipoprotein B (apoB), especially in patients with mild-to-moderate hypertriglyceridemia (2–10 mmol/L). Non-HDLC includes the assessment of remnant lipoprotein cholesterol and shall be reported in all standard lipid panels. Additional apoB measurement can detect elevated LDL particle (LDLP) numbers often unidentified on the basis of LDLC alone. Reference intervals of lipids, lipoproteins, and apolipoproteins are reported for European men and women aged 20–100 years. However, laboratories shall flag abnormal lipid values with reference to therapeutic decision thresholds. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|